Dr. Goy Discusses the Impact of the Roche/Foundation Medicine Partnership

Andre Goy, MD
Published: Wednesday, Jan 14, 2015



Andre Goy, MD, MS chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the impact of Roche’s recent acquisition of the molecular testing company Foundation Medicine.

One of the major benefits of this collaboration is its potential to further innovation, says Goy. By joining together, Roche and Foundation Medicine can push forward with the development of new diagnostics technology, which Goy predicts will either be naked DNA or circulating tumor cell (CTC) assays.

Goy says both of these technologies make it significantly easier to diagnosis new cancers, identify reoccurring cancers, and better understand responses while patients receive treatment, all without using invasive techniques.



Andre Goy, MD, MS chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the impact of Roche’s recent acquisition of the molecular testing company Foundation Medicine.

One of the major benefits of this collaboration is its potential to further innovation, says Goy. By joining together, Roche and Foundation Medicine can push forward with the development of new diagnostics technology, which Goy predicts will either be naked DNA or circulating tumor cell (CTC) assays.

Goy says both of these technologies make it significantly easier to diagnosis new cancers, identify reoccurring cancers, and better understand responses while patients receive treatment, all without using invasive techniques.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x